Aaron Goodman/X
Nov 9, 2024, 15:35
Aaron Goodman: 5-year follow-up of POLARIX
Aaron Goodman, Hematologist/Oncologist and an Associate Professor of Medicine at the University of California, shared a post on X:
“5-year follow-up of POLARIX.
5 year PFS
- P-RCHP = 64.2%
- RCHOP = 59.1%
No significant difference in OS
- P-RCHP = 82.2%
- RCHOP = 79.6%
In 2024 for newly diagnosed advanced stage DLBCL what do you recommend for treatment?
- RCHOP
- Pola-RCHP
- DA-EPOCH-R
- Depends (GCB vs non-GCB).”
More posts featuring Aaron Goodman.
Aaron Goodman is a Hematologist/Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12